Your login session will expire after 30 seconds and you will lose unsaved information
Do you want to extend session?
extend your session [30]

Depuis 2017, le consortium BIORCELL3D® regroupe des chercheurs en Biologie et Pharmaco-chimie de l’équipe de Recherche IMoST (UMR INSERM-UCA 1240) et des spécialistes de l'industrie des Biotechnologies issus des sociétés BIOPASS et BIOMARQUEURS (Clermont-Ferrand - 63). Ensemble, ils développent et commercialisent des OUTILS DE BIOTECHNOLOGIE INNOVANTS APPLIQUÉS À LA CANCÉROLOGIE ET À LA SANTÉ HUMAINE, tels que:

  • Artificial Tumours® (3D cultures) for new cancer drugs screening. These preclinical models are derived from well-known tumour cell lines that are widely used by researchers and that faithfully reproduce avascular micro-tumours. They are available as a service or as ready-to-use kits (Opti3D® kits).
  • Calf serum-free culture media to optimise 3D cultures and allow the preservation of biological samples over several days without freezing (OptiPASS® media range).
  • Fluorescent reagents capable of measuring the level of resistance of tumour cells following anticancer treatments in a rapid and dynamic manner (Patent registered LightSpot® by UCA-BIOMARQUEURS).
  • Services: custom development of new 3D models, screening of molecules (drug screening) or efficacy tests using artificial tumours.

The products

Artificial Tumor Kits® in ready-to-use microplates for in vitro testing.

Artificial tumors® (3D cultures) from tumor cell lines widely used in oncology, and in particular derived from aggressive triple-negative breast cancers.

  • Artificial tumors more closely mimic the microenvironment of avascular tumors in vivo than 2D cultures
  • These models are increasingly becoming part of the drug development processes.

Complete, ready-to-use serum-free cell culture media.

OptiPASS® media used for monolayer (2D) culture of tumour or healthy cells and for 3D culture of a wide range of tumour types of pre-clinical/clinical interest.

Three applications:

Bioproduction-2D culture

For the 2D culture of VERO E6 cells, the OptiPASS® medium (OPTI04) allows:

  • Cell proliferation and viability similar to serum medium culture (reference
  • Preservation of cell phenotype

(Requires prior coating of culture plates)

Oncology- 3D culture

Examples of 3D cultures with OptiPASS® medium: tumour lines validated in 2D and 3D cultures:

  • Breast: MDA-MB-231, SUM1315, BT474
  • Prostate: PC-3
  • Lung : NCI-H1975
  • Ovary: SK-OV-3

For artificial tumour cultures®, the OptiPASS® medium (OPTI03) allows:

  • Maintaining / increasing the rate of proliferation / growth
  • Maintenance of metabolic gradients within cultures (live cells/dead cells)
  • Reproducibility of production in terms of size and proliferation/growth

Once produced, the 3D cultures can be stored for several days in OptiPASS® (OPTI05), under anoxic conditions and at 4°C before being analysed. Examples of tumour lines validated with this method: breast: MDA-MB-231, SUM1315.


Innovation improving the detection, localisation and quantification of MultiDrug Resistance proteins in all cellular samples.

  • Better control of efflux: kidney, liver, blood-brain barrier, placental barrier, etc
  • Evaluate cellular resistance to different molecules and exogenous agents (active ingredients, pollutants, anti-infectious agents)


  • Optimising cancer treatment by quantifying chemoresistance of certain drugs
  • Improving efflux modulation

Available for different excitation/emission wavelengths.

Service provision

Development of new 3D tumour cell models on demand.
  • Analysis of requirements according to the cell type and choice of the most suitable 3D technique
  • Identification of optimal growing conditions:
    • Choice of culture device (specific microplates)
    • Cell concentrations, type and matrix concentration (if applicable)
    • Objective: reproducibility and stability of models (coefficient of variation in size <10%)
  • Characterisation of models:
    • Growth profile
    • Metabolic profile
    • Maximum cultivation time
    • Topology (Scanning Electron Microscopy SEM)
    • Ultrastructure (Transmission Electron Microscopy TEM)
    • Expression profile of proteins of interest
  • Deliverables:
    • 3D cell culture protocol adapted to your cell type
    • Ready-to-use kits containing your 3D models (if development possible in OptiPASS®)
  • Estimated development time: between 2 and 3 months depending on the models
Development of new 3D tumour cell models on demand.
  • Requirement analysis
  • Choice of tumour models
  • Development of adapted tests (when appropriate)
  • Identification of treatment modalities / duration / type of exposure / doses
  • Reception and preparation of test molecules
  • Carrying out the tests
  • Identification of deliverables (non-exhaustive)
    • Viability %, Growth inhibition, IC50,
    • Impact on the cell cycle
    • Tagging and quantification of targets of interest
    • Clonogenic tests, etc.
  • Secure archiving of raw and analysed data
  • Deliverables: full analysis reports
  • Deliverables: full analysis reports

Documentation and videos

Presentation of the screening service

For more details on Biocell3D® products and services, brochures are available for download.

LightSpot        Artificial Tumour Kits® and serum-free culture media


Head of cell culture and therapy projects in France

Port. 07 63 62 19 98

    Would you like more information or technical advice?        Our teams are here to advise you!

x Close